Cord Blood News 9.27 July 13, 2017 | |
| |
TOP STORYScientists investigated the mechanism of a major mitophagy regulator controlling lipid metabolism and therapeutic potential of umbilical cord blood-derived human mesenchymal stem cells. They revealed that Bcl2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)-dependent mitophagy is important for reducing mitochondrial reactive oxygen species accumulation, anti-apoptosis, and migration under hypoxia. [Redox Biol] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)A three-dimensional coculture system constructed using human umbilical cord MSCs and umbilical vein endothelial cells encapsulated in gelatin methacryloyl (GelMA) hydrogels was evaluated to determine the outcomes of cell-cell interactions in vitro and in vivo. The results revealed that GelMA hydrogels displayed minor cytotoxicity on both cell types. [Acta Biomater] Full Article Researchers studied the probability of relapse (PR) after single-unit unrelated cord blood transplantation (UCBT) in relation to the potential graft-vs.-leukemia effect mediated by natural killer (NK) cells present in the umbilical cord blood by analyzing killer-cell immunoglobulin-like receptors (KIR)-ligand and HLA-C typing of the receptor. In the setting of UCBT, the absence of a C-ligand of inhibitory KIR in the patient was associated with lower PR. [Front Immunol] Full Article Inhibition of Autophagy as a Treatment Strategy for p53 Wild-Type Acute Myeloid Leukemia The authors explored whether inhibition of autophagy can be used as a treatment strategy for acute myeloid leukemia (AML). Steady-state autophagy was measured in leukemic cell lines and primary human CD34+ AML cells with a large variability in basal autophagy between AMLs observed. [Cell Death Dis] Full Article Researchers analyzed, retrospectively, the impact of cord blood unit (CBU) cytomegalovirus (CMV) serostatus on relapse incidence (RI) and two-year non-relapse mortality (NRM) of single-unit CBU transplantation for acute leukemia. The recipients of CMV seropositive and seronegative CBUs showed a comparable RI and two-year cumulative incidence of NRM. [Biol Blood Marrow Transplant] Abstract The authors developed a means of producing a biologically active secretome from amniotic fluid stem cells that is free of all exogenous molecules. They demonstrated that the full secretome is capable of promoting stem cell proliferation, migration and protection of cells against senescence. [Stem Cells Dev] Abstract Investigators examined the ability of decidua basalis mesenchymal stem cells (DBMSCs) to protect endothelial cells from activation through monocyte adhesion, by modulating endothelial proliferation, migration, adhesion and inflammatory marker expression. The interaction between DBMSCs and monocytes reduced endothelial cell proliferation and monocyte adhesion to endothelial cells. [Stem Cells Dev] Abstract Large-Scale Ex Vivo Generation of Human Neutrophils from Cord Blood CD34+ Cells Scientists explored a large-scale ex vivo production of neutrophils from hematopoietic stem cells (HSCs) using a four-stage culture approach in a roller-bottle production platform. They expanded CD34+ HSCs isolated from umbilical cord blood (UCB) using their in-house special medium supplemented with cytokine cocktails and achieved about 49000-fold expansion of cells, among which about 61% were differentiated mature neutrophils. [PLoS One] Full Article Three-Dimensional Nano-Fiber Scaffold for Ex Vivo Expansion of Cord Blood Hematopoietic Stem Cells Investigators studied an ex vivo expansion of cord blood hematopoietic stem cells in a new three-dimensional (3D) polycaprolactone (PCL) nano-scaffold coated with fibronectin (FN). 3D PCL nano-scaffold coated with FN produced significantly higher total nucleated cells and CD34+ cells and had significantly higher homing and self-renewality genes than 2D cell culture and before expansion. [Artif Cells Nanomed Biotechnol] Abstract | |
| |
REVIEWSRole of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia Adult acute myeloid leukemia is often associated with a poor prognosis, with allogeneic transplantation representing the greatest chance of cure for eligible patients. Historically, the preferred donor source is a human leukocyte antigen-matched blood relative, although only approximately 30% of patients have access to such a donor. Alternative donor sources, including matched unrelated donors, umbilical cord blood, and haploidentical related donors, are available for almost every patient and are increasingly being used for patients without a matched related donor. [J Natl Compr Canc Netw] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSViraCyte Completes Phase I Clinical Trial of Viralym-C ViraCyte, LLC announced the successful completion of a Phase I clinical trial using Viralym-C, a “ready to administer” T cell immunotherapy product for the treatment of cytomegalovirus infection in hematopoietic stem cell transplant recipients. [ViraCyte, LLC] Press Release Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer Gamida Cell announced that Ronit Simantov, M.D. will join the company as its new Chief Medical Officer based in the U.S. Dr. Simantov brings more than 20 years of experience in research, development, registration, and launch of hematology and oncology drugs. [Gamida Cell Inc.] Press Release | |
| |
POLICY NEWSMarketing of Unproven Stem Cell–Based Interventions: A Call to Action Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. The authors suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments. [Sci Transl Med] Abstract | Editorial US Lawmakers Seek $1.1 Billion Boost for the NIH The US National Institutes of Health (NIH) would see its budget rise by US$1.1 billion in 2018, to $35.2 billion, under a spending proposal released today by lawmakers in the House of Representatives. [Nature News] Editorial In a Rare Move, FDA Reverses Course on Drug Developed by CEO with Ties to Trump The FDA has changed its tune on an experimental drug for a deadly rare disease, withdrawing a request that the company developing it run another clinical trial. The unusual move comes after President Trump met with the company’s CEO — and promised to speed up what he called a “slow and burdensome” process for drug approvals. [STAT news] Editorial White House’s Dwindling Science Office Leaves Major Research Programs in Limbo US President Donald Trump has pledged to shrink the federal government, and he seems to be starting with science. Nearly six months after taking office, Trump has not chosen a science adviser, and the White House’s Office of Science and Technology Policy has dwindled from around 130 staff members under former president Barack Obama to 35. [Nature News] Editorial
| |
EVENTSNEW 5th Annual European Congress on Clinical & Translational Sciences (EUSTM) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Hematopoietic & Mesenchymal Stem Cells (Loma Linda University) NEW Postdoctoral Associate – Normal & Malignant Hematopoiesis (University of Miami) Postdoctoral Position – Acute Myeloid Leukemia (University Hospital Heidelberg) Postdoctoral Researcher – Acute Myeloid Leukemia (Ohio State University) Senior/Principal Scientist – Stem Cell Research (Plasticell Ltd) Postdoctoral Fellow – Stem Cell Biology and Epigenetics (University of South Carolina) Lab Assistant – Cord Blood and/or Cord Tissue Stem Cell Banking (Cryo-Cell International, Inc.) Postdoctoral Fellow – Prenatally Transplanted Stem Cells (Northwestern University Medical) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|